Advanced Stent Technologies, Inc.
This article was originally published in The Gray Sheet
Pleasanton, California firm will enroll 30 patients at four U.S. centers following FDA approval of a feasibility study evaluating the SLK-View side-access stent for cardiovascular bifurcation disease. The device uses a single-balloon delivery system with a take-off angle of as much as 80 degrees and the ability to register and post-dilate a stent side-hole without deforming the stent structure in the main branch of the artery, AST says. Outside the U.S., the firm expects a CE mark for the SLK-View in the second quarter of 2002...
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.